Targeted Oncology

, Volume 12, Issue 6, pp 705–708 | Cite as

Acknowledgement to Referees

Acknowledgement to Referees

Dear Reader,

As we reach the final issue of Targeted Oncology for 2017, I wish to reflect on another successful year’s achievements, and to thank all those who have contributed their time and effort to guarantee the high quality of our content over the past 12 months.

In 2017, 70 articles have been published in Targeted Oncology; the most popular of these, in terms of downloads from SpringerLink (as of October 2017), have been:

Florczuk M., Szpechcinski A., Chorostowska-Wynimko J. miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives. Targeted Oncology (2017), 12(2):179-200.

Rosen L.S., Jacobs I.A., Burkes R.L. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology (2017), 12(5):599-610.

Kim E.S., Scott L.J. Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer. Targeted Oncology (2017), 12(3):373-383.

Dhillon S. Obinutuzumab: A Review in...

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Personalised recommendations